ADDvise adjusts turnover and revenue forecast for 2014

ADDvise Group has had a positive turnover growth in 2014. However, a slightly weaker than-expected sales in the fourth quarter has resulted in that the previously announced turnover and EBITDA forecast of 149 MSEK and 11 MSEK will not be met. Net sales for the full year 2014 is estimated to approximately 138 MSEK with an EBITDA before acquisition costs of approximately 6.8 MSEK in accordance with IFRS. The corresponding numbers for 2013 amounted to 120 MSEK in net sales and EBITDA before acquisition costs of 6.1 MSEK.

- A shift of orders from the fourth quarter 2014 to the first quarter 2015 is the main reason why the full year forecast will not be met. In return, we have had a historically strong start of 2015, says Rikard Akhtarzand CEO of ADDvise in a comment on today's adjusted forecast.

ADDvise Year-end Report for 2014 will be published on February 19th 2015.  

Rikard Akhtarzand, VD +46 765-25 90 71


About ADDvise Lab Solutions AB

ADDvise Lab Solutions AB (publ) is an expansive group which through its subsidiaries IM-Medico Svenska AB, KEBO Inredningar Sverige AB, ADDvise Tillquist AB, Sonesta Medical AB, Sonesta Medical Inc and Surgical Tables Inc. offers comprehensive solutions in the form of products and services to healthcare and research facilities. ADDvise Group's customers are located in both the private and public sectors. The Company's share is listed on First North and Mangold Fondkommission AB, +46 8-503015 50, is the company's Certified Adviser and liquidity provider.

About Us

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. The Group has sales of about 250 MSEK. ADDvise shares are listed on Nasdaq First North Premier. Additional information is available at